Evidence map›Paper›PMID 38696105›Full record

ReviewCurrent psychiatry reports2024

Vitamin B

Kevin P Kennedy, Jeanne L Alexander, Amir Garakani, Lawrence S Gross, David L Mintz, Tapan Parikh, Janet H Pine, Calvin R Sumner, David A Baron

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current psychiatry reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Transdiagnostic prevention in youth mental health, Part II: interventions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Kevin P KennedyDepartment of Psychiatry, UCLA Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, 760 Westwood Plaza, Suite C8-193, Los Angeles, CA, 90024, USA. kpkennedy@mednet.ucla.edu.
Jeanne L AlexanderPrivate Practice, Berkeley, CA, USA.
Amir GarakaniDepartment of Psychiatry and Behavioral Health, Greenwich Hospital, Greenwich, CT, USA.
Lawrence S GrossDepartment of Psychiatry, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
David L MintzAusten Riggs Center, Stockbridge, MA, USA.
Tapan ParikhDepartment of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Janet H PineDepartment of Psychiatry, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
Calvin R SumnerDepartment of Psychiatry, Charles E. Schmidt College of Medicine of Florida Atlantic University, Boca Raton, FL, USA.
David A BaronDepartment of Psychiatry, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
University of Southern California · USAusten Riggs Center · USFlorida Atlantic University · USGreenwich Hospital · USNorthwestern University · USWestern University of Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewVitamin B RECENT

findingsWe find that high-quality evidence shows no benefit to routine B12 supplementation for mild depressive symptoms or to prevent depression. There is very limited evidence on the role of B12 supplementation to augment antidepressants. No high-quality evidence to date suggests a role for routine B12 supplementation in any other major psychiatric disorder. No formal guidelines indicate when clinicians should test B12 levels for common psychiatric symptoms, in the absence of major risk factors for deficiency or cardinal symptoms of deficiency. No robust evidence currently supports routine B12 supplementation for major psychiatric disorders. However, psychiatrists should be aware of the important risk factors for B12 deficiency and should be able to identify symptoms of B12 deficiency, which requires prompt testing, medical workup, and treatment. Testing for B12 deficiency should be considered for atypical or severe psychiatric presentations.

Indexed as

Dietary SupplementsMental DisordersVitamin B 12Vitamin B 12 DeficiencyHumansVitamin B 12B12 deficiencyB12 supplementationCobalaminDepressionVitamin B12

Identifiers

PMID38696105
OpenAlexW4396585468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.